A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps7083
Abstract: TPS7083Background: Anemia is an important complication of MPN-associated myelofibrosis. There are few effective therapies other than RBC transfusions, and responses to other therapies are typically... read more here.
Keywords: associated myelofibrosis; phase multicenter; anemia; mpn associated ... See more keywords